– Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315 – Posters...
Transformative Scientific Breakthrough Pioneered by Spencer Trask & Co. Venture Osiris Therapeutics NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The...
BioVaxys Technology Corp. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation...
BioVaxys Technology Corp. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation...
SAN FRANCISCO, CALIFORNIA / ACCESSWIRE / January 13, 2025 / TheraVac Biologics (TheraVac), a company developing innovative immunotherapies for neurological...
Halifax, Nova Scotia--(Newsfile Corp. - January 13, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is...
SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facilityUI Pharmaceuticals is looking forward to supporting...
NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis...
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential...
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase...
Dark genome biotech company RyboDyn closes pre-seed fundraise from leading global investors to advance cancer immunotherapy SAN DIEGO, Jan. 9,...
-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE...
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a...
Oslo, 9 January 2025: Reference is made to the stock exchange notices published by Ultimovacs ASA (the "Company") on (i)...
The VENTANA DP 600 slide scanner, part of Roche's Digital Pathology Dx system, is now cleared by the FDA to...
LAS VEGAS, Jan. 8, 2025 /PRNewswire/ -- The Industrial Technology Research Institute (ITRI) initiated its presence at CES 2025 with an...
Continued Strong Clinical Progress and Planned New Combination Trial Provide Significant Momentum for 2025NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE)...